Media, investors, advocacy organizations and others, please contact us here.
For US healthcare professionals only
The purpose of this Travere Therapeutics Medical Affairs website is to support healthcare professionals with scientific information. This website is also a channel for US healthcare professionals to submit questions or connect with Travere Therapeutics US healthcare professionals. The information provided is for educational purposes only and is not intended to promote any products. By continuing to use this site you are acknowledging that you are a US healthcare professional
Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Patients With IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)
Sparsentan vs Irbesartan in Patients With Immunoglobulin A Nephropathy (IgAN): Subgroup Analyses of 2-Year Results From the Pivotal Phase 3 PROTECT Trial Presentation
Pegtibatinase, an Investigational Enzyme Replacement Therapy for the Treatment of Classical Homocystinuria (HCU): Latest Findings From the COMPOSE® Phase 1/2 Trial
Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)